BridgeBio

Over the past several weeks, our management team had the opportunity to engage with investors and industry leaders at healthcare conferences hosted by UBS, Jefferies, Piper Sandler, and Evercore ISI. These forums continue to be important touchpoints for sharing our recent progress and reinforcing our commitment to advancing genetically driven therapies for patients in need. We are grateful for the thoughtful conversations and strong engagement from the investment community. Thank you for creating impactful platforms that bring together innovators across the life sciences. We look forward to continued collaboration as we work to deliver meaningful therapies for patients.

We’re proud to share that Neha Gandhi, Executive Director and Head of Global Patient Advocacy, LGMD at BridgeBio will join a panel discussion hosted by Critical Path Institute (C-Path).   For six years, RDCA-DAP has advanced rare disease research by expanding an open-access rare disease data repository, building a collaborative, partner-enabled data ecosystem, and providing public tools that support drug development and analytics. We are proud to have been one of the first industry partners to contribute to this data-sharing effort, supporting #raredisease research by sharing natural history data from our LGMD program.   This webinar will highlight real-world examples of how data sharing accelerates progress from addressing unmet needs to enabling regulatory-grade solutions.   🔗 Register for the webinar: https://bit.ly/4iTYext

In a recent conversation with Luke Timmerman on The Long Run, our founder & CEO, Neil Kumar expands on how clear constraints, such as high technical probability, NPV-positive programs, and an aspiration to best- or first-in-class medicines, guide every decision we make. This episode goes beyond strategy and into the mindset behind building a durable biotech: 🔹 Why an “objective function first” framework matters 🔹 How a disciplined portfolio model enables scale without losing focus 🔹 Lessons from 10 years of navigating scientific risk, capital markets, and patient need 🎧 Listen to the conversation for a deeper look at how BridgeBio approaches long-term impact: https://bit.ly/4o5r66M

“On my perfect day, I’d beat my dad in a race. I’d run a mile. I’d go shopping without getting tired. I’d play tag and do gymnastics again.”  For teens living with limb-girdle muscular dystrophy (#LGMD), these everyday wishes carry extraordinary meaning. We are deeply appreciative of those who share their voices – they remind us to listen, learn, and focus on what matters most.     At BridgeBio, these perspectives inspire our values of science, urgency, and community as we work toward developing treatments for people living with this condition. 💚     💚Follow us here for the next chapter of Sophie, Brooklyn, & Sammy’s story or learn more about LGMD on our website: https://lnkd.in/dttSst7u  

Mary’s story reminds us that #ADH1 may be underdiagnosed and   underrecognized. Across her family, calcium issues span generations, highlighting how often this condition may be overlooked and part of the recognition is listening.     💙Follow along for the next chapter of Mary’s story or learn more about ADH1 at bridgebio.com/adh1 #LifeWithADH1 

We’re proud to participate in the Cardiovascular Clinical Trialist (#CVCT2025) Forum 2025, where we will share new data and insights through two poster presentations focused on advancing understanding and care in transthyretin amyloid cardiomyopathy (ATTR-CM). We will share encore data on the post-hoc analysis of long-term clinical results of our TTR stabilizer in patients with ATTR-CM and early heart failure severity, as well as an update on our partnership with the Cardiovascular Data Science (CarDS) Lab on our patient-led digital registry. We’re honored to collaborate with leading investigators and institutions to advance research that could improve outcomes for people living with ATTR-CM.

Many people living with limb-girdle muscular dystrophy (#LGMD) wait years for an accurate diagnosis.    Even after being told that they have LGMD, the journey doesn’t end there because knowing the exact subtype is essential to managing care.    One form, LGMD2I/R9, is caused by mutations in the FKRP gene, and it can’t be confirmed without genetic testing.    There are no approved therapies for LGMD2I/R9, but early, accurate diagnosis can open doors to options and hope.    Learn more about how to access no-cost testing: https://lnkd.in/eRVbcmzW     

We’re pleased to announce that we will participate in fireside chats at the following upcoming healthcare investor conferences: 📅 Piper Sandler Healthcare Conference, New York, NY Tuesday, December 2 at 10:30 am ET 📅 Evercore ISI HealthCONx Conference, Miami, FL Wednesday, December 3 at 3:00 pm ET 🔗 https://bit.ly/4oZw3iX

We’re excited to introduce new updates to MyAchonJourney! This one-stop educational resource, developed in collaboration with advocacy leaders and healthcare experts, now includes guidance for two new age groups: • Middle childhood (ages 6-12) • Teenage years (ages 13-17) These additions build on existing resources for early childhood, ensuring families have access to reliable information at every stage of their journey. Explore the latest updates here: myachonjourney.com

At our BridgeBio October Town Hall, we celebrated recent clinical milestones in LGMD2I/R9 and ADH1 programs. We also recognized continued commercial progress of our therapy for ATTR-cardiomyopathy. Guided by our values of putting patients first, thinking independently, and making every minute count, leaders across R&D, Commercial, and our international team shared what this moment means and how we are preparing for the road ahead. We are grateful to every teammate, partner, clinician, and advocate who keeps patients at the center of everything we do. Together, we remain focused on translating scientific progress into meaningful impact for the communities we serve.